We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Momenta (MNTA) to Receive $50M Under CSL Collaboration
Read MoreHide Full Article
Momenta Pharmaceuticals, Inc. announced that it has entered into an exclusive research collaboration and worldwide license agreement with CSL Limited.
Momenta’s share price has outperformed the Zacks classified Medical Biomed/Genetics in the last twelve months. The stock gained 14.3% during that period, compared to a decline of 17.4% for the industry.
As per the license agreement, both the companies have agreed to develop and commercialize Fc multimer proteins, including Momenta's M230.
M230, a selective immunomodulator of Fc receptors, is expected to enter the clinic later in 2017.
As per the terms of the agreement, Momenta will receive a $50 million upfront license fee from CSL. The company is entitled to receive future milestone and royalty payments for M230 for upto $550 million. Momenta owns the option to elect a cost and profit sharing arrangement, for which Momenta would fund a proportion of global development and commercialization costs in exchange for a share of profits in the U.S. along with milestones and royalties outside the U.S.
Additionally, both the companies plan to enter into a research collaboration to develop additional Fc multimer proteins that may originate from Momenta's or CSL's research. Moreover, Momenta has the option to enter into an agreement to co-promote M230 and any other collaboration product in the U.S.
The transaction is expected to close in the first quarter of 2017, subject to customary closing conditions.
Notably, the company has collaborated with a few other firms to advance its pipeline. Momenta has also collaborated with Mylan to develop, manufacture and commercialize six of its current biosimilar candidates, including M834 a biosimilar version of Orencia. The company also has a collaboration and license agreement with Novartis’s generic arm (NVS - Free Report) Sandoz for Glatopa and Enoxaparin Sodium Injection.
Cambrex’s earnings estimates increased from $2.46 to $2.55 for 2016 and from $2.91 to $3.06 for 2017 over the last 90 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 19.78%. Its share price has increased 26.7% in the last twelve months.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Momenta (MNTA) to Receive $50M Under CSL Collaboration
Momenta Pharmaceuticals, Inc. announced that it has entered into an exclusive research collaboration and worldwide license agreement with CSL Limited.
Momenta’s share price has outperformed the Zacks classified Medical Biomed/Genetics in the last twelve months. The stock gained 14.3% during that period, compared to a decline of 17.4% for the industry.
As per the license agreement, both the companies have agreed to develop and commercialize Fc multimer proteins, including Momenta's M230.
M230, a selective immunomodulator of Fc receptors, is expected to enter the clinic later in 2017.
As per the terms of the agreement, Momenta will receive a $50 million upfront license fee from CSL. The company is entitled to receive future milestone and royalty payments for M230 for upto $550 million. Momenta owns the option to elect a cost and profit sharing arrangement, for which Momenta would fund a proportion of global development and commercialization costs in exchange for a share of profits in the U.S. along with milestones and royalties outside the U.S.
Additionally, both the companies plan to enter into a research collaboration to develop additional Fc multimer proteins that may originate from Momenta's or CSL's research. Moreover, Momenta has the option to enter into an agreement to co-promote M230 and any other collaboration product in the U.S.
The transaction is expected to close in the first quarter of 2017, subject to customary closing conditions.
Notably, the company has collaborated with a few other firms to advance its pipeline. Momenta has also collaborated with Mylan to develop, manufacture and commercialize six of its current biosimilar candidates, including M834 a biosimilar version of Orencia. The company also has a collaboration and license agreement with Novartis’s generic arm (NVS - Free Report) Sandoz for Glatopa and Enoxaparin Sodium Injection.
Momenta currently carries a Zacks Rank #4 (Sell).
MOMENTA PHARMA Price and Consensus
MOMENTA PHARMA Price and Consensus | MOMENTA PHARMA Quote
Key Pick in the Sector
Cambrex Corporation ) sports a Zacks Rank #1(Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.
Cambrex’s earnings estimates increased from $2.46 to $2.55 for 2016 and from $2.91 to $3.06 for 2017 over the last 90 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 19.78%. Its share price has increased 26.7% in the last twelve months.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>